Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report

European Journal of Medical Research

Jianming Tan¹  Shunliang Yang¹  Weizhen Wu¹  Lianming Liao¹  Junqi Guo¹  Zhixian Wu¹ 

[1] Organ Transplant Institute, Fuzhou General Hospital, Xiamen University, 156 West Er’huan Road, Fuzhou 350025, China

关键词: Iron deficiency;    Immunosuppressive;    Erythropoietin;    Calculated creatinine clearance;    Anemia;   

Others  :  817776
DOI  :  10.1186/2047-783X-18-45

 received in 2013-05-10, accepted in 2013-11-06,  发布年份 2013

【 摘 要 】

Background

Post-transplant anemia (PTA) has long been a less-recognized complication in kidney transplant recipients, and its prevalence also tends to be underestimated. This study sought to evaluate the prevalence, management, and risk factors of PTA from a group of long-term follow-up Chinese kidney transplant recipients.

Methods

One hundred and fifty-four adult kidney transplant recipients were followed up at Fuzhou General Hospital, China, and retrospectively studied.

Results

PTA prevalence at transplant and at 5-yearly time points after transplantation were 45.5%, 10.7%, 9.6%, 14.8%, 13.5%, and 19.6%, respectively. Overall, 38.3% of patients had been anemic at least once during the follow-up period, and 42% of these patients had recurrent anemia. Correlation analysis indicated that hemoglobin levels were associated with graft function. No correlations between anemia and age, gender, immunosuppressive regimens, or antihypertensive agents were observed. Binary logistic regression analysis suggested that serum creatinine and blood urea nitrogen were associated with the diagnosis of anemia at 1 year post-transplant. At 5 years post-transplant, only serum creatinine concentrations correlated with anemia. Although iron drugs are frequently used, erythropoietin was rarely administered in those anemic patients suffering poor graft function that necessitated such therapies.

Conclusions

The prevalence of PTA is noticeably high, and impaired kidney graft function seemed to be the major risk factor for anemia. There is an urgent need to improve current PTA management and to establish modified guidelines for this common complication in kidney transplant recipients.

【 授权许可】

   
2013 Wu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Beshara S, Birgegard G, Goch J, Wahlberg J, Wikstrom B, Danielson BG: Assessment of erythropoiesis following renal transplantation. Eur J Haematol 1997, 58:167-173.
• [2]Mann JF: What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol. Dial Transplant 1999, 14(Suppl 2):29-36.
• [3]Xie YP, Xiao QZ, Zhou YQ, Wu HQ, Hu LQ: Rapid differential diagnosis of thalassemia trait and iron-deficiency anemia with stepwise regression analysis. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:609-611.
• [4]van Dullemen HM, Luykx-de Bakker S, Hillen PH, Van Landeghem AA, Van Boven WP, van der Heul C: Inhibitors of recombinant human erythropoietin in chronic renal failure. Neth J Med 1992, 41:56-63.
• [5]Fernandez Fresnedo G, Palomar R, Rodrigo E, Ruiz JC, De Francisco AL, Cotorruelo JG, Arias M: Prevalence of anemia in renal transplant patients: results from MOST, an observational trial. Transplant Proc 2005, 37:3821-3822.
• [6]Kahng K, Kang C, Kwak J: Changes in hemoglobin levels after renal transplantation. Transplant Proc 1998, 30:3023-3024.
• [7]Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT: Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997, 100:2310-2314.
• [8]Gossmann J, Kachel HG, Schoeppe W, Scheuermann EH: Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993, 56:585-589.
• [9]Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007, 7:243-248.
• [10]Vanrenterghem Y: Anemia after kidney transplantation. Transplantation 2009, 87:1265-1267.
• [11]Sollinger HW: Mycophenolatemofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
• [12]Ott U, Busch M, Steiner T, Wolf G: Anemia after renal transplantation: an underestimated problem. Transplant Proc 2008, 40:3481-3484.
• [13]Borrows R, Loucaidou M, Chusney G, Borrows S, Tromp JV, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D: Anaemia and congestive heart failure early post-renal transplantation. Nephrol Dial Transplant 2008, 23:1728-1734.
• [14]Yabu JM, Winkelmayer WC: Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol 2011, 6:1794-1801.
• [15]Malyszko J, Oberbauer R, Watschinger B: Anemia and erythrocytosis in patients after kidney transplantation. Transpl Int 2012, 25:1013-1023.